Arciénega II, Brunet JF, Bloch J, Badaut J. Cell locations for AQP1, AQP4 and 9 in the non-human primate brain. Neuroscience. 2010;167(4):1103–14.

Article  PubMed  Google Scholar 

Ikeshima-Kataoka H. Neuroimmunological implications of AQP4 in astrocytes. Int J Mol Sci. 2016;17(8):1306.

Article  PubMed  PubMed Central  Google Scholar 

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13:279.

Article  PubMed  PubMed Central  Google Scholar 

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–89.

Article  PubMed  PubMed Central  Google Scholar 

Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet Lond Engl. 2004;364(9451):2106–12.

Article  CAS  Google Scholar 

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73.

Article  PubMed  Google Scholar 

Mewes D, Kuchling J, Schindler P, Khalil AAA, Jarius S, Paul F, et al. Diagnosis of Neuromyelitis Optica Spectrum Disorder (NMOSD) and MOG antibody-Associated Disease (MOGAD). Klin Monatsbl Augenheilkd. 2022;239(11):1315–24.

Article  PubMed  Google Scholar 

Dinoto A, Sechi E, Flanagan EP, Ferrari S, Solla P, Mariotto S, et al. Serum and cerebrospinal fluid biomarkers in Neuromyelitis Optica Spectrum Disorder and myelin oligodendrocyte glycoprotein Associated Disease. Front Neurol. 2022;13:866824.

Article  PubMed  PubMed Central  Google Scholar 

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. [MOG encephalomyelitis: international recommendations on diagnosis and antibody testing]. Nervenarzt. 2018;89(12):1388–99.

Article  CAS  PubMed  Google Scholar 

Carta S, Höftberger R, Bolzan A, Bozzetti S, Bonetti B, Scarpelli M, et al. Antibodies to MOG in CSF only: pathological findings support the diagnostic value. Acta Neuropathol (Berl). 2021;141(5):801–4.

Article  CAS  PubMed  Google Scholar 

Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2023 [cited 2023 Sep 13]; https://doi.org/10.1007/s00415-023-11910-z.

Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D’Anna L, Huss A, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18(3):158–72.

Article  CAS  PubMed  Google Scholar 

Eng LF, Vanderhaeghen JJ, Bignami A, Gerstl B. An acidic protein isolated from fibrous astrocytes. Brain Res. 1971;28(2):351–4.

Article  CAS  PubMed  Google Scholar 

Saraste M, Bezukladova S, Matilainen M, Sucksdorff M, Kuhle J, Leppert D, et al. Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTI. Mult Scler Relat Disord. 2021;50:102810.

Article  CAS  PubMed  Google Scholar 

Björklund H, Eriksdotter-Nilsson M, Dahl D, Rose G, Hoffer B, Olson L. Image analysis of GFA-positive astrocytes from adolescence to senescence. Exp Brain Res. 1985;58(1):163–70.

Article  PubMed  Google Scholar 

Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998;64(3):402–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Varhaug KN, Torkildsen Ø, Myhr KM, Vedeler CA. Neurofilament Light Chain as a Biomarker in Multiple Sclerosis. Front Neurol. 2019 [cited 2023 Aug 2];10. Available from: https://www.frontiersin.org/articles/https://doi.org/10.3389/fneur.2019.00338.

Mandelkow EM, Mandelkow E. Biochemistry and Cell Biology of tau protein in Neurofibrillary Degeneration. Cold Spring Harb Perspect Med. 2012;2(7):a006247.

Article  PubMed  PubMed Central  Google Scholar 

Ren AH, Soosaipillai A, Mathew A, Nikolenko G, Sardesai L, Stengelin M, et al. Utility of a fifth-generation ultrasensitive prostate-specific Antigen assay for monitoring prostate Cancer patients after Radical Prostatectomy with 3 years of Follow-Up. Clin Chem. 2020;66(10):1329–38.

Article  PubMed  Google Scholar 

Diamandis EP, Stanczyk FZ, Wheeler S, Mathew A, Stengelin M, Nikolenko G, et al. Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS). Clin Chem Lab Med. 2017;55(11):1789–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing: R Core Team. 2023. Available from: https://www.R-project.org/.

Steyerberg EW, Harrell FE, Borsboom GJJM, Eijkemans MJC, Vergouwe Y, Habbema JDF. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54(8):774–81.

Article  CAS  PubMed  Google Scholar 

Harrell FE, Slaughter J. Regression modeling strategies: with applications to Linear models, logistic regression, and Survival Analysis. Springer; 2001.

Yang Z, Wang KKW. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38(6):364–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012;4(147):147ra111.

Article  PubMed  PubMed Central  Google Scholar 

Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69(2):239–45.

Article  PubMed  Google Scholar 

Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler Houndmills Basingstoke Engl. 2012;18(1):113–5.

Article  CAS  Google Scholar 

Palace J, Leite MI, Nairne A, Vincent A. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. 2010;67(8):1016–7.

Article  PubMed  Google Scholar 

Waters PJ, Pittock SJ, Bennett JL, Jarius S, Weinshenker BG, Wingerchuk DM. Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol. 2014;5(3):290–303.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cohen M, De Sèze J, Marignier R, Lebrun C. False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients. Mult Scler Houndmills Basingstoke Engl. 2016;22(9):1231–4.

Article  CAS  Google Scholar 

Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78(9):665–71. discussion 669.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fu Y, Bi J, Yan Y, Sun X, Li K, Kim SY et al. Rapid Immunodot AQP4 Assay for Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2023 [cited 2023 Sep 7]; https://doi.org/10.1001/jamaneurol.2023.2974.

Watanabe M, Nakamura Y, Michalak Z, Isobe N, Barro C, Leppert D, et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology. 2019;93(13):e1299–311.

Article  CAS  PubMed  Google Scholar 

Aktas O, Smith MA, Rees WA, Bennett JL, She D, Katz E, et al. Serum glial fibrillary acidic protein: a Neuromyelitis Optica Spectrum Disorder Biomarker. Ann Neurol. 2021;89(5):895–910.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim H, Lee EJ, Lim YM, Kim KK. Glial Fibrillary Acidic Protein in Blood as a Disease Biomarker of Neuromyelitis Optica Spectrum Disorders. Front Neurol. 2022 [cited 2022 Nov 7];13. Available from: https://www.frontiersin.org/articles/https://doi.org/10.3389/fneur.2022.865730.

Schindler P, Grittner U, Oechtering J, Leppert D, Siebert N, Duchow AS, et al. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neuroinflammation. 2021;18(1):105.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem Res. 2000;25(9–10):1439–51.

Article  CAS  PubMed  Google Scholar 

Wang KK, Yang Z, Zhu T, Shi Y, Rubenstein R, Tyndall JA, et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn. 2018;18(2):165–80.

Article  PubMed  PubMed Central  Google Scholar 

Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018;8(1):14798.

Article  CAS  PubMed  PubMed Central  Google Scholar